| Status: Excluded due to NICE appraisal | |
Product meets AWMSG criteria due to NICE appraisal TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | atezolizumab (Tecentriq®) |
| Formulation | 840 mg, 1200 mg concentrate for solution for infusion |
| Reference number | 4471 |
| Indication | Monotherapy as adjuvant treatment following complete resection for adult patients with Stage II to IIIA (7th edition of the UICC/AJCC-staging system) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and whose disease has not progressed following platinum-based adjuvant chemotherapy |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 01/02/2022 |
| NICE guidance | TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer |
| Commercial arrangement | PAS |